BioCentury

7:00 AM GMT, Aug 1, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Apixaban: Phase III data

Bristol-Myers and Pfizer reported data from the discontinued, double-blind, international Phase III APPRAISE-2 trial in 7,392 ACS patients showing that twice-daily 5 mg apixaban plus mono or dual antiplatelet therapy

Read the full 306 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.